Funding for this research was provided by:
National Cancer Institute (P50CA196530, P30CA016359)
National Institutes of Health (R01 CA227473, K24CA172123, P50 CA121974)
Received: 21 January 2019
Accepted: 11 July 2019
First Online: 23 July 2019
Ethics approval and consent to participate
: The study was approved by the Yale Human Investigation Committee protocol #9505008219 and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent or waiver of consent in circumstances stipulated by the HIC protocol.
: Not applicable.
: D.L. Rimm has served as a consultant, advisor or served on a Scientific Advisory Board for Amgen, Astra Zeneca, Agendia, Biocept, Bristol-Meyers Squibb, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, Merck, NanoString, PerkinElmer, PAIGE, and Ultivue. He has received research funding from Astra Zeneca, Cepheid, Navigate/Novartis, NextCure, Lilly, Ultivue, and PerkinElmer. H.M. Kluger has served as a consultant for Corvus, Nektar, Biodesix, Genentech, Pfizer, Merck and Celldex, and has received research support from Merck, Apexigen and Bristol-Meyers Squibb. All other authors have no competing interests.